| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 3.0 | — |
| Net income | -25.8 | -11.9 |
| EPS (diluted, $ a share) | $-0.18 | $-0.12 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: MIST. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Milestone Pharmaceuticals Inc.: key numbers
- Share price
- $0.3650Close, Nov 16
- Market cap
- $45.4M
- Shares outstanding
- 124.5MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Milestone Pharmaceuticals Inc.
All →Milestone Pharmaceuticals Financial Results
Milestone Pharmaceuticals reported Q3 2026 financial results, highlighting $1.0 million in net product revenue for CARDAMYST and a 73% increase over the prior quarter. The company announced a 30% reduction in operating expenses, including leadership departures and bringing its sales force in-house, to extend its cash runway into late 2028. This extension is designed to fund operations through the anticipated Phase 3 data readout for etripamil in AFib-RVR expected in 2H 2028.
- Term
- Q3 2026
“We are encouraged by the early progress of CARDAMYST, and as we gain experience in the market, we believe we are better able to identify where our investments can have the greatest potential impact. The actions we are announcing today reflect a more efficient approach to capital allocation, which we believe will drive continued prescription growth, expand our prescriber base and improve patient access for CARDAMYST, while reducing operating expenses.”
Joseph Oliveto, President and Chief Executive Officer
Milestone Pharmaceuticals Nasdaq/NYSE Compliance Notice
Milestone Pharmaceuticals received a deficiency notice from Nasdaq on October 23, 2026, because its common shares failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. The company has until April 21, 2027, to regain compliance by having its shares close at $1.00 or higher for at least 10 consecutive business days.
- Counterparty
- Nasdaq
- Term
- 180 days